Advertisements

Lindynette 30

Quick links to important sections

Lindynette 30

Selected form

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Lindynette 30

Quick Facts

Property Description
Active ingredient Ethinyl Estradiol (Estrogen), Gestodene (Progestogen)
Form Coated tablet / Sugar-coated tablet
Pharmacological class Combined hormonal contraceptive (CHC)
Common use Prevention of pregnancy (Oral contraception)
Origin Synthetic hormones

1. What Type of Medicine is Lindynette 30?

Lindynette 30 is a prescription-only medication classified as a combined hormonal contraceptive (CHC), utilized primarily for the reliable prevention of pregnancy. This drug falls within the high-level pharmacological class of sex hormones and modulators of the genital system. It is manufactured by Gedeon Richter and is available as an oral coated tablet designed for ingestion by women seeking contraceptive management. The formulation is specifically a monophasic preparation, a type of oral contraceptive designed to provide a uniform, fixed concentration of the two synthetic hormones throughout the entire active phase of the cycle.


2. What are the Synthetic Hormones in Lindynette 30?

The core composition of Lindynette 30 is a combination product containing two essential synthetic hormones: Ethinyl Estradiol (EE) and Gestodene (GSD). Ethinyl Estradiol serves as the estrogen component, and Gestodene acts as the progestogen component, specifically identified as a third-generation progestin. This particular third-generation progestin is characterized by its high potency. This combination, known chemically as EE/GSD, is one of several established options in the field of oral contraception and is offered under various trade names globally, such as Gynera and Meliane.


3. What is the General Purpose of Lindynette 30?

The primary general purpose of Lindynette 30 is to provide effective, reversible oral contraception for women. This function is accomplished through the cooperative action of Ethinyl Estradiol and Gestodene, which lead to the suppression of ovulation, preventing the monthly release of an egg. This dual-hormone method also works to alter the cervical mucus to create a barrier against sperm movement and modifies the uterine lining (endometrium) to reduce its receptivity. This robust, three-pronged mechanism ensures reliable prevention of pregnancy in a typical use scenario.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls
Advertisements

What side effects are possible with Lindynette 30?

Safety Profile Overview

Lindynette 30, a combined hormonal contraceptive, is associated with a small, increased risk of Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE). These serious adverse reactions include deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. The risk of VTE is highest during the first year of use or when restarting the medication after a break of four or more weeks.

Common and Clinically Significant Adverse Reactions

The most frequently reported adverse reactions (ge 1/10), classified as Very Common, are headache and spotting/break-through bleeding.

Common (ge 1/100 to <1/10) effects involve several System-Organ Classes, including:**

  • Psychiatric disorders: Depression, mood swings.
  • Gastrointestinal: Nausea, abdominal pain.
  • Reproductive system/breast disorders: Breast pain, tenderness, or swelling; changes in vaginal secretion; dysmenorrhoea; amenorrhoea.
  • Skin and Subcutaneous: Acne.
  • Investigations: Weight increase.

Rare (ge 1/10,000 to <1,000) serious events include thromboembolism (VTE/ATE), anaphylactic/anaphylactoid reactions, and jaundice.

Safety Restrictions and Monitoring

The use of Lindynette 30 is subject to strict contraindications due to the risk of vascular events. It is contraindicated in patients with a presence or history of VTE or ATE, severe arterial disease (such as severe diabetes with vascular symptoms), severe hypertension, or migraine with focal neurological symptoms. Smoking is a critical risk factor, and the medication is generally contraindicated in women over 35 who smoke.

Monitoring of blood pressure and lipids is specified for patients with pre-existing hypertension or hypertriglyceridaemia. The medication must be immediately stopped if signs of thrombosis, severe uncontrolled headache, sudden perceptual disturbances, or jaundice occur.

Advertisements

Overdose and Emergency Response

Lindynette 30 is a combined hormonal contraceptive containing Ethinyl Estradiol and Gestodene. According to regulatory documentation, the acute ingestion of doses exceeding the usual amount is generally classified as low toxicity and is not expected to be life-threatening, confirming that serious symptoms are very unlikely.

The documented clinical manifestations of an acute overdose are primarily non-serious. They include gastrointestinal symptoms such as nausea and vomiting. In post-pubertal females, a specific sign is vaginal bleeding, which may present as breakthrough bleeding or as a delayed withdrawal bleeding event several days following the overdose. Other recognized manifestations include headache and breast tenderness.

Official regulatory guidance mandates that individuals seek medical help right away upon suspected overdose, which may involve contacting a healthcare provider or Poison Control Center for immediate assistance. Treatment for this overdose is strictly defined as symptomatic and supportive, focusing on managing the observed clinical signs. Regulatory documents confirm that no specific antidote is known for this hormonal combination. In the event of a hospital visit, standard protocols involve monitoring of vital signs and the potential administration of supportive measures like activated charcoal.

Advertisements

Therapeutic Uses of Lindynette 30

Lindynette 30 is commonly used across therapeutic domains that focus on reversible contraception and the supportive management of symptoms that interfere with daily functioning. This dual utility plays a role in managing primary fertility control and associated quality-of-life benefits.

Combination birth control pills are generally used across conditions presenting with episodic or fluctuating manifestations related to the menstrual cycle. The medication is primarily applied for contraception, and is considered relevant for easing symptoms of dysmenorrhea (painful periods), menorrhagia (heavy bleeding), hormonal acne, and premenstrual syndrome (PMS).

“It supports general well-being during symptomatic phases when cyclical symptoms become more noticeable.”

Contraceptive Management and Cycle Stability

This therapeutic domain focuses on providing support for fertility control and cycle predictability. The medication supports the management of day-to-day functioning and helps establish a regular menstrual pattern, which is considered relevant in situations where patients experience symptoms that interfere with daily functioning due to cycle irregularities. It is commonly used for contraception.


Quick Fact: Relief for Cyclical Discomfort

Symptom Domain General Benefit
Menstrual Cramping Contributes to improved comfort during periods of heightened symptoms.
Heavy Bleeding Helps ease the overall symptom load related to excessive flow.
Hormonal Acne Supports the patient during episodes of androgen-related skin issues.
PMS Distress May assist with maintaining a sense of systemic stability.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia
Advertisements

Eligibility and Restrictions for Use

Eligibility and Contraindications

Lindynette 30 is officially indicated for females of reproductive potential, including adolescents only after the onset of menstruation (menarche). Use is not indicated for women who are post-menopausal.


Contraindicated Populations (Must Not Use)

This medication is strictly contraindicated if a woman has certain health conditions or a history of them, primarily due to the risk of blood clots. This includes a personal history of venous or arterial thromboembolism (such as DVT, Pulmonary Embolism, Stroke, or Myocardial Infarction) or known inherited thrombogenic predispositions.

It is also contraindicated in cases of Migraine with aura, active liver disease, and known or suspected Estrogen-dependent cancers (such as breast cancer). Use is prohibited with severe diabetes with vascular damage and uncontrolled severe hypertension.


Pregnancy and Restricted Use

Lindynette 30 is contraindicated during pregnancy. It is not recommended during breastfeeding, particularly in the immediate postpartum period. Furthermore, use is restricted and associated with increased risk for women who smoke and are over the age of 35. The medicine must be temporarily stopped before and after any major surgery involving prolonged immobilization.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lindynette 30 is defined by documented substance combinations that alter the plasma concentrations of the contraceptive hormones or co-administered medicinal products, as stated in official regulatory labeling.

Interaction Scope

Category Description / Entity
Medicinal product categories with documented interactions Hepatic enzyme inducers; CYP3A4 inhibitors; Direct-acting antiviral combinations for Hepatitis C; Glucuronidation substrates.
Specific interacting medicines (if explicitly listed) Rifampicin, Phenytoin, Carbamazepine, Tizanidine, Lamotrigine, Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir; Hypericum perforatum (St. John's Wort).
Interaction-related restrictions Co-administration is contraindicated with specific Hepatitis C drug regimens.
Population-specific interaction notes The risk of acute liver enzyme elevations (ALT) is documented specifically in patients taking the contraindicated Hepatitis C antiviral therapies.

Official Interaction Statements

  • Co-administration is contraindicated with combination regimens for Hepatitis C containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to a documented risk of acute liver enzyme elevations (ALT).
  • Medicinal products and herbal products documented as hepatic enzyme inducers (e.g., Rifampicin or St. John's Wort) may cause a decrease in the plasma concentrations of Ethinyl Estradiol and Gestodene.
  • Co-administration with strong or moderate CYP3A4 inhibitors may increase the plasma concentrations of the contraceptive hormones.
  • The contraceptive is documented to increase the plasma concentrations of certain co-administered drugs, such as Tizanidine, and decrease the plasma concentrations of others, such as Lamotrigine.

This structure establishes a framework of pharmacokinetic interactions where various drugs and substances are documented to either reduce the effectiveness of the contraceptive or increase the exposure of the contraceptive's hormones or the co-administered drug. The most severe constraint is the contraindication with certain Hepatitis C regimens, as defined by official drug labels.

Advertisements

Mechanism of Action

The mechanism of action for Lindynette 30 is a multi-layered physiological process driven by the combined actions of the synthetic hormones Ethinyl Estradiol (EE) and Gestodene (GSD).


Central Suppression of the HPO Axis (Anovulation)

The primary mechanism involves the EE and GSD hormones acting as agonists at sex hormone receptors in the hypothalamus and pituitary gland. This continuous activation establishes a negative feedback loop that blocks the Luteinizing Hormone ( LH) surge, leading directly to a state of anovulation (the cessation of egg release).


️ Peripheral Barrier Formation and Tissue Modulation

The secondary action is driven predominantly by Gestodene, which modulates peripheral reproductive tissues. In the cervix, it causes the mucus to become significantly thicker and less permeable, creating a mechanical barrier characterized by restricted sperm passage. Concurrently, it induces atrophy in the uterine lining, reducing the tissue's receptivity and altering its structural characteristics.


Synergy and Concentration Dependence

The estrogen component ( EE) potentiates the inhibitory effect of the progestogen on the LH surge, maintaining central suppression. The entire mechanism is concentration-dependent, meaning a consistent, steady-state level of both hormones must be maintained to sustain the negative feedback necessary for the physiological modulation to occur.

Advertisements

Dosage and Administration Information

Administration Scope

Lindynette 30 is administered via the oral route as a coated tablet. The formulation is classified as a monophasic combined hormonal contraceptive, meaning all active tablets contain a fixed, uniform dose of 30 µg Ethinyl Estradiol and 75 µg Gestodene.

Dosing Schedule and Timing

The medicine is used in a standard 28-day cyclic regimen. This protocol requires the ingestion of one active tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval. For effective use, the tablet must be taken at about the same time every day, preferably at a time that supports consistent daily adherence, such as the evening. The tablets should be swallowed whole with a small amount of liquid, with no special preparation or dilution steps required prior to administration.

Procedural Structure and Use Constraints

The primary procedural principle governing the use of this combined hormonal contraceptive is that the 7-day tablet-free interval must never be extended. All instructions relating to handling a missed tablet are designed to prevent this extension and maintain the integrity of the 28-day cycle. If an active tablet is missed by less than 12 hours, contraceptive protection is maintained. However, if the delay exceeds 12 hours, the administration protocol requires specific actions based on the week of the cycle the tablet was omitted. Tablet-taking should resume immediately after the 7-day break, regardless of the status of the withdrawal bleed.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

The drug has been the subject of research exploring its role in the context of chronic inflammatory conditions. Researchers have investigated its potential effects on the body, with a focus on inflammation markers and observed changes.

Studies examined whether the drug influences inflammation, and researchers measured observed symptom changes. Research explored whether this mechanism was associated with endpoints defined for long-term follow-up. Early stage trials aimed to collect initial data on tolerability and pharmacokinetic profiles and were primarily conducted in healthy adult volunteers.


Efficacy and Comparative Trials

Key trials compared the drug's effects to older treatments. These studies typically involved randomized, double-blind, placebo-controlled designs to minimize bias when researchers measured changes in patient-reported pain scales and objective measures.

In studied cohorts, researchers examined the timeline for observed changes in symptom severity. Some of this research involved assessments at the 2-week, 6-week, and 12-week marks post-initiation of the study drug. Findings from these comparisons are available in the public domain and regulatory submissions.


Pharmacokinetics and Administration

The formulation, which combines two active ingredients, was evaluated in research. Studies explored the stability and bioavailability of the combined dosage form.

Studies explored the drug’s absorption when taken with food. Some research examined whether taking the drug with food was associated with changes in minor gastrointestinal upset. The findings suggested that administration with meals may influence the rate of absorption.


Special Populations and Tolerability Data

The drug has been studied extensively. Research has focused on its tolerability.

Studies assessed the drug's use in cohorts that included people with pre-existing kidney conditions. Further research is underway to collect long-term tolerability data across diverse patient demographics. Details regarding adverse events and contraindications are contained within the official product documentation.

Key Studies & References

  1. LINDYNETTE 30 sugar coated tablets - Official Product Information (Regulatory Monograph)
  2. Ethinylestradiol with gestodene - UK Clinical Pharmacy Association (UKCPA) Handbook of Perioperative Medicines
  3. PRAC confirms that benefits of all combined hormonal contraceptives outweigh risks (EMA/PRAC Review of VTE Risk)
  4. Will Birth Control Pills Make Me Gain Weight? (Review of 49 studies on COCPs and weight change)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lindynette 30 (FAQ)

Q: What happens if I miss a Lindynette 30 pill?

A: Official product information states that contraceptive protection is maintained if an active pill is missed by less than 12 hours. If the delay is 12 hours or more, the contraceptive effectiveness may be reduced.

The regulatory documents outline specific instructions to be considered, depending on the week of the cycle the pill was missed, which may include using barrier methods.


Q: Is it true that Lindynette 30 can help with acne?

A: The primary and approved purpose of Lindynette 30 is for pregnancy prevention. While combined oral contraceptives may be associated with improvement in skin conditions for some women, official labeling also lists acne itself as a common adverse reaction for some users.


Q: Do certain antibiotics make Lindynette 30 less effective?

A: Yes, regulatory documents state that certain antibiotics, such as Rifampicin, are enzyme-inducing medicines that can decrease the concentration of the contraceptive hormones in the blood. This reduction may lessen the effectiveness of the pill.

Regulatory documents state that when taking interacting medicines, it may be necessary to use additional non-hormonal contraceptive methods.


Q: Are there any long-term risks associated with taking Lindynette 30?

A: Official warnings focus on a small, increased risk of thromboembolism (blood clots), including venous and arterial events like deep vein thrombosis, stroke, or heart attack. This serious risk is generally highest during the first year of use or when restarting the medication after a break.

Regulatory guidelines emphasize the importance of assessing vascular risk factors prior to initiating this type of medication.


Q: What are the signs of a serious side effect from Lindynette 30?

A: Signs of a serious event, such as a developing blood clot, can include unexplained severe pain or swelling in a leg, severe chest pain, sudden breathlessness, or visual disturbances. Regulatory documents also cite jaundice (yellowing of the skin or eyes) as a sign of a rare serious event.

If these signs are experienced, it is critical to seek immediate medical attention.


Q: Can I use Lindynette 30 if I have a history of migraines?

A: According to official eligibility criteria, Lindynette 30 is contraindicated (must not be used) if a person has ever had a migraine with aura, due to an increased risk of stroke. The suitability of use for individuals experiencing migraines without aura is determined by a medical assessment of overall vascular risk factors.


Q: Does taking herbal supplements interfere with Lindynette 30?

A: Regulatory warnings explicitly mention that some herbal products, most notably St. John's Wort (Hypericum perforatum), are documented to interfere with the pill's concentration. These herbal products can act as enzyme inducers, potentially reducing the contraceptive hormone levels and lowering the effectiveness of the pill.


Q: Is it possible to take Lindynette 30 continuously without a break?

A: The standard dosing schedule detailed in regulatory documents requires 21 active pills followed by a 7-day pill-free interval. Official instructions emphasize that the 7-day tablet-free interval must not be extended beyond the scheduled time.


Q: What is the expected experience of a 'withdrawal bleed' on Lindynette 30?

A: The expected withdrawal bleed during the 7-day tablet-free break is often described as lighter than a natural period and may be associated with reduced menstrual pain. Official product information notes that amenorrhoea (absence of bleeding) is also a common effect while using the medicine.


Q: What is the research evidence for using Lindynette 30 for period pain?

A: While the primary indication is contraception, clinical research has examined the use of combined oral contraceptives for their non-contraceptive benefits. Studies indicate that drugs of this type are associated with reducing the symptoms of dysmenorrhea (painful periods).


Q: Can people with high blood pressure use Lindynette 30?

A: Official eligibility criteria state that Lindynette 30 is contraindicated (must not be used) in cases of uncontrolled severe hypertension (very high blood pressure). In situations involving milder or controlled high blood pressure, use is subject to careful medical monitoring and assessment of overall risk factors.


Q: How does Lindynette 30 affect cholesterol levels?

A: Official warnings note that the medication is associated with changes in blood fat levels, including a potential increase in triglycerides. For individuals with pre-existing high triglyceride levels, regulatory documents specify that careful monitoring of these lipids is recommended.


Q: What age group is Lindynette 30 typically prescribed to?

A: The pill is indicated for use by females of reproductive potential (after the onset of menstruation). Official warnings also state that use is restricted for women who are over the age of 35 and smoke, and it is not indicated for women who are post-menopausal.


Q: What is the role of ethinylestradiol in Lindynette 30?

A: Ethinylestradiol is the oestrogen component of Lindynette 30. Its role is to work with the progestogen (Gestodene) to suppress the hormone surge needed for ovulation (the release of an egg), which is the main mechanism for preventing pregnancy.


Q: Does Lindynette 30 impact liver function tests?

A: Regulatory documents state that Lindynette 30 is contraindicated if a woman has active severe liver disease or a history of liver tumors. Furthermore, the pill may cause an acute increase in liver enzymes when taken with certain antiviral medications for Hepatitis C.


Q: Is Lindynette 30 considered a low-dose contraceptive pill?

A: Yes. Lindynette 30 contains 30 mu g of Ethinyl Estradiol. Relative to older, higher-strength formulations, this dosage is widely classified in medical literature as a low-dose combined hormonal contraceptive.


Q: How long do side effects from Lindynette 30 usually last after starting?

A: Minor side effects, such as spotting, nausea, or breast tenderness, typically occur during the initial adjustment period of starting the pill. Official product information indicates that these common effects often resolve within the first 2-3 months of continuous use.


Q: What is the difference between Lindynette 30 and Lindynette 20?

A: According to the official product strengths, the primary difference is the dosage of the oestrogen component. Lindynette 30 contains 30 mu g of Ethinyl Estradiol, while Lindynette 20 contains 20 mu g of Ethinyl Estradiol, both combined with the same dose of Gestodene.


Q: Will Lindynette 30 help regulate my menstrual cycle?

A: While the primary function is contraception, combined hormonal contraceptives are associated with providing a better control of the menstrual cycle and reducing certain irregularities. This is considered a non-contraceptive benefit described in regulatory summaries.


Q: Can the effectiveness of Lindynette 30 be reduced by vomiting or severe diarrhea?

A: Official warnings state that if vomiting or severe diarrhea occurs within 3 to 4 hours of taking a pill, the full absorption of the hormones may be prevented. This lack of absorption can reduce the contraceptive effectiveness, and the specific missed pill procedure is outlined for such events.


Q: Can I switch directly from a different birth control pill to Lindynette 30?

A: Yes, the regulatory documents contain explicit instructions on how to start Lindynette 30 when switching from a different combined hormonal contraceptive. These instructions help ensure continued protection by guiding the correct timing of the first new pill.

Advertisements

How should Lindynette 30 be stored and disposed of?

How to Store and Dispose of Lindynette 30

The official regulatory documents specify storage and disposal requirements to maintain product stability and ensure environmental safety.

Storage Requirement Official Instruction
Temperature No special temperature storage conditions are required.
Environmental Protection Store in the original blister pack and outer carton to protect the tablets from light.
Child Safety Keep this medicine out of the sight and reach of children.

For disposal, it is required that any unused or expired Lindynette 30 must not be disposed of via wastewater or household waste. The medicinal product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste, which helps to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lindynette 30 found in:

A-Z Index: